Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy
- PMID: 9142733
- DOI: 10.1007/BF01267684
Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy
Abstract
It is crucial to predict drug effectiveness in chronic disease, such as dilated cardiomyopathy (DCM), in which the left ventricular (LV) function might be improved by beta-blocker therapy. As the functional improvement effected by beta-blocker therapy takes more than 2 months, we investigated whether iodine-123 metaiodobenzylguanidine (123I-MIBG) imaging could be used to predict drug effectiveness. We studied 13 patients (11 men and two women; mean age, 43+/-13 years) with DCM and seven normal subjects (six men and one woman; mean age, 48+/-16 years). We obtained myocardial single-photon emission tomography (SPET) images 15 min and 4 h after administration of 123I-MIBG (111 MBq). Studies were performed in the patients with DCM before and 1 and 3 months after the administration of metoprolol and in the normal subjects. We calculated the regional 123I-MIBG washout rate (r-WR) in the SPET image, and the global 123I-MIBG washout rate (g-WR) and heart-mediastinum activity ratio (H/M) using the anterior planar image. We classified patients into those showing a >/=5% increase in LV ejection fraction (LVEF) at 3 months compared with LVEF values before the treatment (group I, n=7) and those showing a <5% increase in LVEF (group II, n=6). In group I, the r-WR values at pretreatment and at 1 month and 3 months of treatment, respectively, were 36%+/-19%, 29%+/-14%* and 25%+/-13%* in the anterior segment, 39%+/-17%, 33%+/- 17%** and 28%+/-17%* in the lateral segment, 36%+/- 16%, 31%+/-14%* and 22%+/-12%** in the septal segment and 40%+/-11%, 37%+/-19% and 31%+/-18%* in the inferior segment; the g-WR was 45%+/-11%, 43%+/-10% and 34%+/-9%*, respectively (* P<0.05, ** P<0.01 vs pretreatment). In group II, there were no significant changes in regional or global parameters during the 3-month period. In normal subjects, the r-WR values in each of the anterior, lateral, septal and inferior segments were significantly lower than those in groups I and II. These values were 18%+/-9%, 18%+/-15%, 20%+/-12% and 21%+/-15%, respectively. This study demonstrated that with regional assessment 123I-MIBG SPET imaging can be used to predict the functional improvement of LVEF at 1 month of beta-blocker therapy in patients with DCM.
Similar articles
-
Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy--Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography.Am Heart J. 2001 Apr;141(4):645-52. doi: 10.1067/mhj.2001.112783. Am Heart J. 2001. PMID: 11275933
-
[Prediction of effect of beta-blocker therapy in patients with dilated cardiomyopathy by using 123I-BMIPP, 123I-MIBG scintigraphy].Kaku Igaku. 2001 Mar;38(2):99-104. Kaku Igaku. 2001. PMID: 11345771 Japanese.
-
Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy.Am Heart J. 1997 Mar;133(3):353-8. doi: 10.1016/s0002-8703(97)70232-1. Am Heart J. 1997. PMID: 9060806
-
Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of beta-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis.Eur J Nucl Med Mol Imaging. 2004 Oct;31(10):1356-61. doi: 10.1007/s00259-004-1557-2. Epub 2004 Jun 19. Eur J Nucl Med Mol Imaging. 2004. PMID: 15221293 Clinical Trial.
-
Quantitative scintigraphic analysis of 123I-MIBG by polar map in patients with dilated cardiomyopathy.Nucl Med Commun. 1997 Mar;18(3):219-29. doi: 10.1097/00006231-199703000-00005. Nucl Med Commun. 1997. PMID: 9106775
Cited by
-
Prediction of the response to beta-blocker therapy in patients with dilated cardiomyopathy: comparison of 123I-MIBG scintigraphy and low-dose dobutamine stress echocardiography.J Echocardiogr. 2009 Dec;7(4):74-9. doi: 10.1007/s12574-009-0022-4. Epub 2009 Sep 11. J Echocardiogr. 2009. PMID: 27278462
-
Prediction of sudden cardiac death in patients with chronic heart failure by regional washout rate in cardiac MIBG SPECT imaging.J Nucl Cardiol. 2019 Feb;26(1):109-117. doi: 10.1007/s12350-017-0913-0. Epub 2017 May 12. J Nucl Cardiol. 2019. PMID: 28500540
-
I-123 MIBG scintigraphy in idiopathic dilated cardiomyopathy: where next?J Nucl Cardiol. 2002 Jan-Feb;9(1):127-30. doi: 10.1067/mnc.2002.121175. J Nucl Cardiol. 2002. PMID: 11845138 No abstract available.
-
What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients?J Nucl Cardiol. 2012 Dec;19(6):1198-205; quiz 1206-10. doi: 10.1007/s12350-012-9612-z. J Nucl Cardiol. 2012. PMID: 22956185 Review. No abstract available.
-
Very long-term follow-up data of non-ischemic idiopathic dilated cardiomyopathy after beta-blocker therapy: recurrence of left ventricular dysfunction and predictive value of 123I-metaiodobenzylguanidine scintigraphy.Heart Vessels. 2019 Feb;34(2):259-267. doi: 10.1007/s00380-018-1245-y. Epub 2018 Aug 24. Heart Vessels. 2019. PMID: 30143883
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials